The article presents the results of the study BCD-085-7 (PLANETA, NCT03390101), performed on the clinical base of the Krasnodar Clinical Dermato-Venereological Dispensary. Eleven patients were randomized into three groups: 3 persons — in the group receiving 120 mg netakimab every 2 weeks after induction in weeks 0, 1, 2; 6 — in the group receiving 120 mg netakimab every 4 weeks after induction in weeks 0, 1, 2; 2 — in the placebo group. The results. Positive dynamics in the majority of patients was noted after the initiating course and tends to increase in the future. By the 12th week of therapy, the PASI75 response had reached 3 (100%) patients who received netakimab once in 2 weeks; 5 (83.3%) patients who used netakimab once in 4 weeks; the PASI90 response was 33.3 and 50%, respectively. In the placebo group in the 12th week of therapy there was no response of PASI75 and PASI90 in any case. The high efficacy of netakimab was confirmed by itching and its positive effect on the quality of life of patients. The drug showed a favorable safety profile, there were no significant differences between the groups (p=0.443), during the study there were no cases of serious adverse events and adverse events of the 4th degree of severity, as well as cases of early withdrawal because of them.